OchreBio Profile Banner
Ochre Bio Profile
Ochre Bio

@OchreBio

Followers
785
Following
201
Media
290
Statuses
610

Breaking the silence of a top ten global killer: Chronic liver disease.

Oxford, UK
Joined August 2020
Don't wanna be here? Send us removal request.
@OchreBio
Ochre Bio
1 year
🚀 Announcing our new multi-year data license agreement with @GSK to investigate the drivers of #liverdisease! . Read the announcement ➡️ .
Tweet media one
0
8
33
@OchreBio
Ochre Bio
11 hours
4.5M US adults live with chronic liver disease, & transplant demand far outpaces donors. In a recent @MayoClinic video, Dr. Bashar Aqel talks about the anxious waits for life-saving surgery that many patients face while their conditions deteriorate. 🎥
Tweet media one
0
0
0
@OchreBio
Ochre Bio
2 days
The NHS 10-Year Plan signals a shift toward earlier intervention, genomics, & smarter care systems. It’s great to see a national strategy reflect the importance of understanding disease biology & using AI to build more efficient, data-rich systems.
0
0
0
@OchreBio
Ochre Bio
7 days
Liver therapies are undergoing their most significant disruption in decades. In @thetimes, @Quin_Wills discusses how metabolic drugs like Wegovy & Mounjaro are moving us from symptom control to targeted therapies. Read the full article:
0
0
0
@OchreBio
Ochre Bio
8 days
RT @healthtechworld: Oxford-based @OchreBio, a biotechnology company developing RNA therapeutics for chronic liver disease, has appointed D….
0
1
0
@OchreBio
Ochre Bio
8 days
AI is reshaping how we diagnose and treat disease. In @DailyMailUK, @LaraLewington explores this shift, featuring our work using machine learning and human liver data to develop RNA therapies for late-stage disease. Article 👉
Tweet media one
0
1
2
@OchreBio
Ochre Bio
9 days
🎉 Huge congratulations to the Ochre team who completed Sunday’s @raceforlife for @CR_UK!. Support the team here👉
Tweet media one
1
0
0
@OchreBio
Ochre Bio
11 days
Announcing Dr. @QuinWills as the new CEO of Ochre Bio 👏 . As founder & former CSO, Quin has shaped our RNA therapy strategy from day one. He now leads Ochre into it's next phase: progressing new drug candidates toward the clinic. 🔗
Tweet media one
0
0
2
@OchreBio
Ochre Bio
14 days
In just 6 years, Jenna went from managing an autoimmune condition to liver failure. She got a transplant just in time – but many aren't as lucky. A powerful reminder of how fast liver disease can progress and how long the wait for transplant can be. 🔗
Tweet media one
0
0
0
@OchreBio
Ochre Bio
15 days
We've been included in @BloombergUK & @Founders_Forum's 25 European companies to watch in 2025!. Grateful to be highlighted for our work in advanced liver disease, alongside other innovative companies in genAI, auto vehicles, space & biotech.🚀. Full list➡️
Tweet media one
0
0
0
@OchreBio
Ochre Bio
21 days
Rezdiffra is showing promise in compensated MASH cirrhosis. At #EASL, Madrigal shared 2-year data: 65% of patients with CSPH at baseline moved to lower-risk categories. Fibrosis markers, liver stiffness and portal pressure also improved. 🔗
0
1
1
@OchreBio
Ochre Bio
21 days
Read the Lancet study 👉
0
0
0
@OchreBio
Ochre Bio
21 days
Over 15 million in the US, UK, Germany & France may be living with MASH & don’t know it. That means higher risk of chronic liver disease without diagnosis or treatment. Early detection is vital, but we also need better ways to treat what we find. 🔗
1
0
0
@OchreBio
Ochre Bio
23 days
Among the jam-packed conference schedule, Quin also sat down with Nasdaq’s Elsa Givan to share his vision for 2030 – including a rapid-fire Q&A on curiosity, creativity, and biotech’s future. Thanks @sxswlndn for the opportunity to share our science!.
0
0
0
@OchreBio
Ochre Bio
23 days
However, for Quin, this work is personal. His path as a biotech founder and his experience as a patient with liver disease all drive his focus on developing effective therapies for chronic liver disease.
1
0
0
@OchreBio
Ochre Bio
23 days
That was the thread running through our Founder @QuinWills' talk at @sxswlndn – on a stage next to a perfused human liver and some big questions about how we treat liver disease.
1
0
0
@OchreBio
Ochre Bio
23 days
Great AI in drug R&D needs great human data. While algorithms deserve the glory they're receiving, the true pioneers are the scientists figuring out novel ways to produce translatable human data. Watch the presentation:
Tweet media one
Tweet media two
1
0
2
@OchreBio
Ochre Bio
28 days
🩺 In 2005, Anthony was told he had “fatty liver”, which came with no warning signs. After 9 yrs of fat buildup, he learned he had cirrhosis & liver cancer. He had felt fine the whole time. Stories like this remind us of how silent liver disease can be. 🔗
0
0
1
@OchreBio
Ochre Bio
1 month
AI in drug discovery is no longer a ‘what if’. It’s here. What’s changing is what drives value. A new @Nature biopharma dealmakers piece highlights our innovative collaboration with @GSK & how deals are shifting toward high-quality human data. Read:
0
0
1
@OchreBio
Ochre Bio
1 month
🚨 @Quin_Wills is on stage today at #SXSWLondon. 🕒 14:30–14:55 | Truman Brewery Stage 1. He’ll share how we combine machine learning with human-first lab models to move beyond animal testing & improve drug discovery for liver disease. Dont miss out 👉
Tweet media one
0
1
2
@OchreBio
Ochre Bio
1 month
📊 Weight-loss medications are showing significant benefits, particularly for liver health. In @thetimes, our Founder & CSO @QuinWills explores what this means for liver disease & cirrhosis, & why these first-gen therapies are only part of the story. 🔗
Tweet media one
0
0
0